The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
An Open-Label, Two-Arm, Phase I Trial of Recombinant Human Interleukin-21 in Patients with Metastatic Melanoma
Abstract
Purpose: Human interleukin-21 (IL-21) is a pleiotropic class I cytokine that activates CD8+ T cells and natural killer cells. We report a phase 1 study of recombinant human IL-21 in patients with surgically incurable metastatic melanoma. The primary objective was to investigate safety and tolerability by determining dose-limiting toxicity (DLT). The secondary objectives were to identify a dose response for various biomarkers in the peripheral blood, estimate the minimum biologically effective dose, determine the pharmacokinetics of IL-21, determine if anti-IL-21 antibodies were induced during therapy, and measure effects on tumor size according to Response Evaluation Criteria in Solid Tumors. Experimental Design: Open-label, two-arm, dose escalation trial of IL-21 administered by i.v. bolus injection at dose levels from 1 to 100 μg/kg using two parallel treatment regimens: thrice weekly for 6 weeks (3/wk) or three cycles of daily dosing for 5 days followed by 9 days of rest (5+9). Results: Twenty-nine patients entered the study. IL-21 was generally well tolerated and no DLTs were observed at the 1, 3, and 10 μg/kg dose levels. In the 3/wk regimen, DLTs were increased in alanine aminotransferase, neutropenia, and lightheadedness with fever and rigors. DLTs in the 5+9 regimen were increased in aspartate aminotransferase and alanine aminotransferase, neutropenia, fatigue, and thrombocytopenia. The maximum tolerated dose was declared to be 30 μg/kg for both regimens. Effects on biomarkers were observed at all dose levels, including increased levels of soluble CD25 and up-regulation of perforin and granzyme B mRNA in CD8+ cells. One partial tumor response observed after treatment with IL-21 for 2 × 6 weeks (3/wk) became complete 3 months later. Conclusions: IL-21 is biologically active at all dose levels administered and is generally well tolerated, and phase 2 studies have commenced using 30 μg/kg in the 5+9 regimen.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., & Thun, M. J. (2007) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.57.1.43 · Cited by 7,439
Interleukin-21 is a growth and survival factor for human myeloma cells
Brenne, A.-T., Baade Ro, T., Waage, A., Sundan, A., Borset, M., & Hjorth-Hansen, H. (2002) · Blood · doi:10.1182/blood.v99.10.3756 · Cited by 168
Cited by
Interleukins, from 1 to 37, and interferon-γ: Receptors, functions, and roles in diseases
Akdis, M., Burgler, S., Crameri, R., Eiwegger, T., Fujita, H., Gomez, E., Klunker, S., Meyer, N., O’Mahony, L., Palomares, O., et al. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.11.050 · Cited by 778
Interleukin-21: Basic Biology and Implications for Cancer and Autoimmunity
Spolski, R., & Leonard, W. J. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090316 · Cited by 696
Interleukin-21: a double-edged sword with therapeutic potential
Spolski, R., & Leonard, W. J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4296 · Cited by 548
Natural killer cell–directed therapies: moving from unexpected results to successful strategies
Terme, M., Ullrich, E., Delahaye, N. F., Chaput, N., & Zitvogel, L. (2008) · Nature Immunology · doi:10.1038/ni1580 · Cited by 289
Determinants of Successful CD8+ T-Cell Adoptive Immunotherapy for Large Established Tumors in Mice
Klebanoff, C. A., Gattinoni, L., Palmer, D. C., Muranski, P., Ji, Y., Hinrichs, C. S., Borman, Z. A., Kerkar, S. P., Scott, C. D., Finkelstein, S. E., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0503 · Cited by 288
Metadata
- Authors
- Davis, I. D., Skrumsager, B. K., Cebon, J., Nicholaou, T., Barlow, J. W., Moller, N. P. H., Skak, K., Lundsgaard, D., Frederiksen, K. S., Thygesen, P., & McArthur, G. A.
- Venue
- Clinical Cancer Research
- Published
- 2007-06-15
- Volume
- 13
- Issue
- 12
- Pages
- 3630-3636
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2138426249
- Cited by
- 164
- References
- 2
- FWCI
- 8.60
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: An Open-Label, Two-Arm, Phase I Trial of Recombinant Human Interleukin-21 in Patients with Metastatic Melanoma. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-07-0410
- The paper
- Davis, I. D., Skrumsager, B. K., Cebon, J., Nicholaou, T., Barlow, J. W., Moller, N. P. H., Skak, K., Lundsgaard, D., Frederiksen, K. S., Thygesen, P., & McArthur, G. A. (2007). An Open-Label, Two-Arm, Phase I Trial of Recombinant Human Interleukin-21 in Patients with Metastatic Melanoma. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-07-0410
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.